Table 2.
Comparison of pre-travel prevalence odds of IgG antibodies against hepatitis E virus (anti-HEV IgG) to exposure history-level grouping among pre-travel participants evaluated by the Boston Area Travel Medicine Network before travel from January 2009 to September 2010
| Hepatitis E exposure level | Anti-HEV IgG (+) pre-travel | Anti-HEV IgG (−) pre-travel | Prevalence odds ratio (95% CI) | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Overall (N = 1,356) | 80 | 6 | 1,276 | 94 | Not applicable |
| Group 1: born in a highly endemic country (N = 152) | 18 | 12 | 134 | 88 | 4.8 (2.3–10.3) |
| Group 2: not born in a highly endemic country but lived in a highly endemic country for at least one year (N = 51) | 2 | 4 | 49 | 96 | 1.5 (0.3–6.7) |
| Group 3: not born in and never lived in a highly endemic country but traveled to a highly endemic country (N = 710) | 48 | 7 | 662 | 93 | 2.6 (1.4–5.0) |
| Group 4: never lived in or traveled to a highly endemic country (N = 443) | 12 | 2 | 431 | 97 | Referent |
CI = confidence interval.